MSA Team Works Toward Publications

March 16, 2020

MSA has submitted three manuscripts in high impact journals that report the results of pre-clinical experiments evaluating the pharmacokinetics (nasal absorption), pharmacodynamics (efficacy), and safety in support of Bryn Pharma’s goal to bring a cost-effective intranasal delivery system for patients with anaphylaxis to market.

MSA authors include Principals Dr. Kenneth Dretchen Ph.D., Zack Mesa, and Michael Mesa, along with MSA associate Matt Robben Ph.D.

MSA News

Dr. Kenneth Dretchen PhD has been appointed as a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) Drug Discovery Research Award Committee.

May 22, 2020 This committee review grant applications for Pre-doctoral, Post-doctoral and Research Starter Grants dealing with innovative approaches that…

Read More

Mesa Science Associates and Bryn Pharma Publish Second Pre-Clinical Study of a New Approach to Treating Anaphylaxis

The second in a series of three studies measured the pharmacokinetic and heart rate effects of intranasal epinephrine in dogs….

Read More

Mesa Science Associates and Bryn Pharma Publish Pre-Clinical Study of a New Approach to Treating Anaphylaxis

April 13, 2020 Mesa Science Associates Inc. (MSA) and Bryn Pharma LLC published the findings from the first of three…

Read More